Table 1 Demographic, clinical, immunological and virological baseline characteristics of patients initiating RPV/TDF/FTC co-formulation between April 1, 2013, and March 31, 2014
From: Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study
Baseline characteristics | Total | cART-naïve patients | cART-experienced patients (n = 596) |
|---|---|---|---|
(n = 644) | (n = 48) | ||
Mean age, years (±SD, median) | 45.8 (±11.1, 46) | 42.3 (±11.3, 44.5) | 46.1 (±11.0, 46) |
Male gender, n (%) | 451 (70.0) | 41 (85.4) | 410 (68.8) |
HIV transmission group, n (%) | |||
MSM | 307 (47.7) | 29 (60.4) | 278 (46.6) |
Heterosexual | 260 (40.4) | 14 (29.2) | 246 (41.3) |
Intravenous drug use | 44 (6.8) | 2 (4.2) | 42 (7.1) |
Othera | 14 (2.2) | 2 (4.2) | 12 (2.0) |
Unknown | 19 (2.9) | 1 (2.0) | 18 (3.0) |
Ethnicity, n (%) | |||
White | 476 (73.9) | 37 (77.1) | 439 (73.7) |
Black | 129 (20.0) | 6 (12.5) | 123 (20.6) |
Hispano-American | 18 (2.8) | 4 (8.3) | 14 (2.3) |
Asian | 20 (3.1) | 1 (2.1) | 19 (3.2) |
Other | 1 (0.2) | 0 (0) | 1 (0.2) |
Mean duration of HIV infection in years (±SD, median) | 11.0 (±7.8, 9.8) | 2.6 (±3.3, 1.5) | 11.7 (±7.7, 10.6) |
History of AIDS disease, n (%) | 91 (14.1) | 0 (0) | 91 (15.3) |
Mean baselineb CD4 count, cells/mm3 (±SD, median)c | 637 (±271, 606) | 478 (±176, 473) | 650 (±273, 620) |
Mean nadir CD4 count, cells/mm3 (±SD, median)d | 283 (±186, 261.5) | 447 (±157, 430) | 270 (±182, 247) |
Baselineb HIV-RNA < 50 copies/mL, n (%)c | 552 (86.1) | 2 (4.2)e | 549 (92.6) |
HBV co-infection (positive AgHBs), n (%) | 32 (5.0) | 0 (0) | 32 (5.4) |
HCV co-infection (positive HCV-RNA), n (%) | 35 (5.4) | 1 (2.1) | 34 (5.7) |